慢性淋巴细胞白血病及其他癌症中罕见的胚系ATM意义不明变异
研究分析336例慢性淋巴细胞白血病(CLL)患者及公共癌症外显子/基因组测序数据(445例CLL、75例套细胞淋巴瘤、216例转移性乳腺癌、140例肺癌),发现三分之二罕见胚系ATM变异为致病性或意义不明(VUS)预测致病性,携带这些变异患者更易通过获得del(11q)发生双等位ATM失活,且与接受新型药物的CLL患者无进展生存期缩短相关。
要点
- 三分之二罕见胚系ATM变异为致病性(18%-50%)或VUS预测致病性(50%-82%),取决于癌症类型,患病率最高达8%。
- 携带致病性及VUS预测致病性变异(均为杂合、多为错义)的患者更易获得del(11q)导致双等位ATM失活,类似于体细胞ATM变异患者。
- 罕见胚系变异与接受新型药物的CLL患者无进展生存期缩短相关,程度与体细胞ATM或TP53破坏相当。
核心结论
- 罕见胚系ATM变异中三分之二为致病性或VUS预测致病性,携带者更易发生双等位ATM失活并与CLL新型药物治疗后无进展生存期缩短相关。
- 结果强调需要确定ATM等临床相关基因中VUS的致病性。
研究设计与样本
- 研究纳入真实世界队列336例慢性淋巴细胞白血病(CLL)患者,并分析公共癌症全外显子/基因组测序数据集:445例CLL、75例套细胞淋巴瘤、216例转移性乳腺癌、140例肺癌患者。
- 对原代CLL细胞进行ATM活性功能测定。
主要发现
- 三分之二罕见胚系ATM变异为致病性(18%-50%)或VUS预测致病性(50%-82%),取决于癌症类型,患病率最高达8%,三分之一为VUS预测良性。
- 携带致病性及VUS预测致病性变异(均为杂合、多为错义)的患者比无这些变异的患者更易通过获得del(11q)发生双等位ATM失活,类似于体细胞ATM变异患者。
- 原代CLL细胞功能测定证明VUS预测致病性ATM变异部分降低ATM活性,合并del(11q)导致ATM活性完全丧失。
- 罕见胚系变异与接受新型药物的CLL患者无进展生存期缩短相关,与体细胞ATM或TP53破坏相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Germline pathogenic ATM (ataxia-telangiectasia mutated) variants are associated with the risk of multiple cancers; however, genetic testing reveals a large number of ATM variants of uncertain significance (VUS). Here, we studied germline ATM variants occurring in a real-world cohort of 336 patients with chronic lymphocytic leukaemia (CLL) and public cancer whole-exome/genome-sequencing datasets (445 CLL, 75 mantle cell lymphoma, 216 metastatic breast cancer, 140 lung cancer patients). We found that two-thirds of rare germline ATM variants are pathogenic (18%-50%) or VUS-predicted pathogenic (50%-82%), depending on cancer type and reaching a prevalence of up to 8%, and one-third are VUS-predicted benign. Patients with both pathogenic and VUS-predicted pathogenic variants, all heterozygous, mostly missense, are more predisposed to biallelic ATM inactivation by acquiring deletion (del)11q than patients without these variants, similar to patients with somatic ATM variants. A functional assay of ATM activity in primary CLL cells proved that VUS-predicted pathogenic ATM variants partially reduce ATM activity and concurrent del(11q) leads to complete loss of ATM activity. The rare germline variants were associated with reduced progression-free survival in CLL on novel agents, comparable to somatic ATM or TP53 disruptions. Our results highlight the need to determine the pathogenicity of VUS in clinically relevant genes such as ATM.
引用
- Petrackova A, Savara J, Turcsanyi P, et al. Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers. Br J Haematol. 2022. PMID: 36029002. doi:10.1111/bjh.18419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。